A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion

被引：0
|
作者：
Berdeja, Jesus G. [1 ,2 ]
Gregory, Tara B. [1 ,3 ]
Faber, Edward [1 ,4 ]
Matous, Jeffrey [1 ,3 ]
Hart, Lowell [1 ,5 ]
Mace, Joseph R. [1 ,6 ]
Arrowsmith, Edward R. [1 ,7 ]
Flinn, Ian W. [1 ,2 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Tennessee Oncol PLLC, Nashville, TN USA
[3] Colorado Blood Canc Inst, Denver, CO USA
[4] Oncol Hematol Care Inc, Cincinnati, OH USA
[5] Florida Canc Specialists, Ft Myers, FL USA
[6] Florida Canc Specialists, St Petersburg, FL USA
[7] Tennessee Oncol PLLC, Chattanooga, TN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.4530.4530
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4530
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
    Liping Liu
    Ningning Zhao
    Wenjun Xu
    Zhixin Sheng
    Lida Wang
    Journal of Hematology & Oncology, 9
  • [22] Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
    Liu, Liping
    Zhao, Ningning
    Xu, Wenjun
    Sheng, Zhixin
    Wang, Lida
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [23] Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Kensei Tobinai
    Masafumi Taniwaki
    Yoshihisa Shumiya
    Toru Nakamura
    Takaaki Chou
    International Journal of Hematology, 2016, 104 : 596 - 604
  • [24] A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
    Vesole, David H.
    Siegel, David Samuel DiCapua
    Richter, Joshua Ryan
    McNeill, Ann
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    McBride, Laura
    Raucci, Laura
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Smith, Judith
    Mato, Anthony R.
    Bilotti, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin J.
    Thomas, Sheeba K.
    Weber, Donna M.
    Wang, Michael
    Alexanian, Raymond
    Qazilbash, Muzaffar H.
    Bashir, Qaiser
    Parmar, Simrit
    Shah, Nina
    Popat, Uday R.
    Orlowski, Robert Z.
    BLOOD, 2012, 120 (21)
  • [26] Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency
    Badros, Ashraf Z.
    Vij, Ravi
    Martin, Thomas
    Zonder, Jeffrey A.
    Woo, Tina
    Wang, Zhengping
    Lee, Susan
    Wong, Alvin
    Niesvizky, Ruben
    BLOOD, 2009, 114 (22) : 1492 - 1492
  • [27] Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
    Chari, Ajai
    Larson, Sarah
    Holkova, Beata
    Cornell, Robert F.
    Gasparetto, Cristina
    Karanes, Chatchada
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Valent, Jason
    Lunning, Matthew
    Usmani, Saad Z.
    Anderson, Larry D., Jr.
    Chang, Lipo
    Lee, Yihua
    Pak, Yvonne
    Salman, Zeena
    Graef, Thorsten
    Bilotti, Elizabeth
    Chhabra, Saurabh
    LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2588 - 2594
  • [28] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [29] A Phase 3 Study of Carfilzomib and Dexamethasone (Kd) in Patients With Relapsed and Refractory Multiple Myeloma (MM) in China
    Du, Juan
    Fang, Baijun
    Li, Jian
    Jin, Jie
    Wang, Shunqing
    Zou, Dehui
    Cai, Zhen
    Wang, Hongxiang
    Hu, Jianda
    Li, Wei
    Fu, Chengcheng
    Shao, Zonghong
    Xia, Zhongjun
    Liu, Peng
    Niu, Ting
    Tang, En-Tzu
    Kimball, Amy
    Hou, Jian
    Chen, Wenming
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E267 - E268
  • [30] PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)
    Bilotti, El
    Vesole, D.
    Richter, J.
    McNeill, A.
    Anand, P.
    Bednarz, U.
    Ivanovski, K.
    McBride, L.
    Raucci, L.
    Batra, V.
    Siegel, D.
    HAEMATOLOGICA, 2013, 98 : 323 - 324
12345